LPCN Lipocine Inc.

Overview and Growth

Fiscal 2025 results for Lipocine Inc. combined $1.98M of revenue with net loss of $9.63M and an operating cash outflow of $9.76M. Revenue of $1.98M sets the scale for evaluating how effectively sales translated into profit and cash during the year. The top line contracted 82.3% from $11.20M in fiscal 2024; this top-line contraction left the company with a smaller revenue base. Diluted earnings per share were -$1.69, translating the period’s attributable earnings into the amount reported for each diluted share. The diluted weighted-average share count was 5.71M, linking total earnings with the per-share result received by shareholders. Diluted shares moved 5.3% from 5.42M in fiscal 2024, leaving the current share base higher year over year. The company employed $17.01M of total assets, the balance-sheet base supporting its current operating and cash-flow results. The revenue-to-assets relationship was 0.12x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

The company recorded an operating loss of $10.37M after the reported operating expense base. Relative to revenue, the operating deficit measured 524.7%, showing the shortfall after operating costs. The company ended the period with a net loss of $9.63M, extending the operating result through all remaining items. Measured against revenue, the bottom-line deficit represented 487.1% after all recognized items. EBITDA was negative $10.31M, showing a deficit before interest, taxes, depreciation, and amortization. The pretax result was a loss of $9.63M, establishing the deficit before tax effects. The pretax loss equaled 487.0% of revenue, measuring the pre-tax deficit against sales. The reported income-tax provision was $200.00, the amount recognized between pretax income and the final net-income result. Relative to period-end equity, the net loss represented 66.5%. The loss-to-assets relationship was 56.6%, placing the bottom-line deficit against the company’s resource base. The bottom line deteriorated from $8.35K of income in fiscal 2024 to a $9.63M loss.

Liquidity and Capital Structure

At period end, the $17.01M asset base was financed through $2.53M of liabilities and $14.48M of equity. Current assets were $16.88M against $2.53M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. Current assets covered current liabilities by 6.68x, leaving a positive buffer for near-term obligations. Cash and equivalents totaled $5.21M, identifying the most liquid reported component available within the broader current-asset balance. The cash balance equaled 205.9% of current liabilities, showing how much near-term coverage came from cash alone. Book equity represented 85.1% of total assets, quantifying the balance-sheet share supported by shareholder capital. Relative to total assets, liabilities measured 14.9%, complementing the separate equity-based view of the company’s capital structure. The cash-to-assets relationship was 30.6%, comparing reported cash and equivalents with the full positive asset balance. Compared with $22.51M in fiscal 2024, the current asset base moved 24.5% and finished lower. Reported equity changed 31.1% from $21.00M in fiscal 2024, placing the current capital base lower year over year. The reported cash balance changed 16.1% from $6.21M in fiscal 2024, ending lower year over year.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $9.76M, rather than cash generation from operations. Compared with a $1.22M operating cash outflow in fiscal 2024, the current outflow increased to $9.76M.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Sep 24, 2026.